Expert Perspectives on Current and Emerging Therapies for AML

Opening their discussion on the management of acute myeloid leukemia (AML), expert oncologists provide an overview on the incidence, diagnosis, and stratification of patients.

Expert perspectives on current classification strategies in acute myeloid leukemia and how these guidelines make use of molecular markers.

In light of novel targeted agents made available to patients with AML, panelists consider the value of timely molecular testing in this setting.

Expert oncologists reflect on risk stratification in acute myeloid leukemia and the process of categorizing patients into ‘fit’ versus ‘unfit’ subsets.

Centering focus on first-line treatment modalities, panelists highlight the ongoing role of intensive chemotherapy in the management of AML.

Expert perspectives on the emergence of FLT3-targeted therapies and their role in the first-line setting of acute myeloid leukemia management.

Shared insight on IDH-mutated acute myeloid leukemia and appropriate first-line treatment options in this setting.

Comprehensive discussion on the emergence of CPX-351 as a first-line treatment option for patients with acute myeloid leukemia.

Expert oncologists highlight challenges in the setting of TP53-mutated AML and consider appropriate treatment strategies.

A brief overview of mainstay treatment options in the first-line setting of AML for patients deemed unfit for intensive chemotherapy.

In the setting of IDH-mutated AML, panelists consider optimal treatment options in patients unfit for intensive chemotherapy.

A comprehensive review of novel venetoclax-based combination therapy in patients unfit for intensive chemotherapy who are diagnosed with AML.

Before closing out their discussion on first-line treatment options for patients with AML, expert oncologists reflect on the role of stem cell transplant in AML.

Centering its discussion on relapsed/refractory acute myeloid leukemia, the panel highlights broader treatment strategies in this setting.

Expert perspectives on the potential role of IDH1-targeted therapy, olutasidenib, in patients with relapsed/refractory acute myeloid leukemia.

Shared insight on how treatments can be optimally sequenced in patients with relapsed/refractory acute myeloid leukemia.

A comprehensive review of emerging treatment options and how they may fit into the treatment landscape of acute myeloid leukemia.

Closing out their discussion on the management of acute myeloid leukemia, expert panelists share their excitement for the future evolution of the treatment landscape.